Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Feb 24;20(1):69.
doi: 10.1186/s12886-020-01346-8.

A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion - an 18-month prospective cohort study

Roderick O'Day  1   2 , Noha Ali  2   3 , Lyndell L Lim  1   2 , Sukhpal Sandhu  1   2 , Thuy Chau  2 , Sanjeewa Wickremasinghe  4   5
Affiliations
Comparative Study

A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion - an 18-month prospective cohort study

Roderick O'Day et al. BMC Ophthalmol. .

Abstract

Background: To evaluate the safety and efficacy of a treat-and-extend protocol of aflibercept for cystoid macular oedema (CMO) secondary to central retinal vein occlusion (CRVO).

Methods: Twenty patients with CMO secondary to CRVO were included in this prospective cohort study. After 3 loading 4-weekly injections, treatment intervals were increased by 2 weeks if there was no clinical activity, to a maximum of 12 weeks. If clinical activity recurred or persisted, the interval between injections was shortened by 2 weeks, to a minimum of 4 weeks. Main outcome measures were change in visual acuity and the proportion of patients gaining 15 or more Early Treatment of Diabetic Retinopathy Study (ETDRS) letters from baseline at 6, 12 and 18 months.

Results: Mean BCVA gain from baseline was 19.7 ± 13.8, 22.2 ± 13.9 and 21.9 ± 15.8 ETDRS letters at 6, 12 and 18 months, respectively. Sixty-five percent of patients gained 15 or more ETDRS letters at 6 months, increasing to 70.6% at 12 and 18 months. Patients received 5.0 [4.0 to 6.0], 8.5 [8.0 to 10.3] and 11.0 [9.0 to 12.5] injections by 6, 12 and 18 months, respectively.

Conclusions: The visual outcomes achieved with a treat-and-extend protocol in this study were similar to the pivotal trials of aflibercept for CMO secondary to CRVO, which used monthly and then as-needed protocols.

Trial registration: Australian and New Zealand Clinical Trials Registry, registration number ACTRN12615000417583, 01/05/2015.

Keywords: Aflibercept; Anti-vascular endothelial growth factor inhibitors; Central retinal vein occlusion; Cystoid macular oedema; Treat-and-extend.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Median number of injections in our ‘treat and extend’ cohort at 6, 12, and 18 months. Vertical lines represent interquartile range
Fig. 2
Fig. 2
Comparison of the mean change in visual acuity (a) and mean change in central macular thickness (b) in our ‘treat and extend’ cohort from baseline with that of the COPERNICUS and GALILEO studies. ETDRS: Early Treatment of Diabetic Retinopathy Study; CMT: central macular thickness
See this image and copyright information in PMC

References

    1. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural History of Visual Outcome in Central Retinal Vein Occlusion. Ophthalmology. 2011;118:119–33.e2. doi: 10.1016/j.ophtha.2010.04.019. - DOI - PMC - PubMed
    1. McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117:1113–23.e15. doi: 10.1016/j.ophtha.2010.01.060. - DOI - PubMed
    1. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155:429–37.e7. doi: 10.1016/j.ajo.2012.09.026. - DOI - PubMed
    1. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124–33.e1. doi: 10.1016/j.ophtha.2010.02.022. - DOI - PubMed
    1. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118:2041–2049. doi: 10.1016/j.ophtha.2011.02.038. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources